Table 6 Valproate trials reported in 2009 and 2010
From: Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Combination therapy | Type of cancer | Phase | N | Outcome (most relevant findings) | Literature |
|---|---|---|---|---|---|
VPA+5-Azacytidine | High risk MDS | II | 62 | 8CR/PR, 4HI, 10SD | Voso et al. (2009) |
VPA+5-Azacytidine+ATRA | High risk AML, MDS | II | 65 | 14PR, 3PR | Raffoux et al. (2010) |
I VPA+Epirubicin | Solid tumors | I/II | I n = 41 | I 9PR | Munster et al. (2009b) |
II VPA+FEC100 |  |  | II n = 14 | II 9 objective response | |
VPA+Karenitecin | Melanoma | I/II | I n = 33 | I MTD = 75 mg/kg/day | Daud et al. (2009) |
II n = 15 | II 7SD | ||||
VPA+Dacarbazine+IFα | Melanoma | I/II | 18 | 1CR, 2PR, 3SD | Rocca et al. (2009) |